-
What is the best choice of follow-up procedure following resection of lung cancer? Lancet Oncol. (IF 54.433) Pub Date : 2022-08-11 Ursula Nestle, Stefan Delorme
Abstract not available
-
A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study Lancet Oncol. (IF 54.433) Pub Date : 2022-08-11 Andreas Kleppe, Ole-Johan Skrede, Sepp De Raedt, Tarjei S Hveem, Hanne A Askautrud, Jørn E Jacobsen, David N Church, Arild Nesbakken, Neil A Shepherd, Marco Novelli, Rachel Kerr, Knut Liestøl, David J Kerr, Håvard E Danielsen
Background The DoMore-v1-CRC marker was recently developed using deep learning and conventional haematoxylin and eosin-stained tissue sections, and was observed to outperform established molecular and morphological markers of patient outcome after primary colorectal cancer resection. The aim of the present study was to develop a clinical decision support system based on DoMore-v1-CRC and pathological
-
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial Lancet Oncol. (IF 54.433) Pub Date : 2022-08-11 Virginie Westeel, Pascal Foucher, Arnaud Scherpereel, Jean Domas, Philippe Girard, Jean Trédaniel, Marie Wislez, Patrick Dumont, Elisabeth Quoix, Olivier Raffy, Denis Braun, Marc Derollez, François Goupil, Jacques Hermann, Etienne Devin, Hubert Barbieux, Eric Pichon, Didier Debieuvre, Fabrice Barlesi
Background Even after resection of early-stage non-small-cell lung cancer (NSCLC), patients have a high risk of developing recurrence and second primary lung cancer. We aimed to assess efficacy of a follow-up approach including clinic visits, chest x-rays, chest CT scans, and fibre-optic bronchoscopy versus clinical visits and chest x-rays after surgery for resectable NSCLC. Methods In this multicentre
-
IASLC 2022 World Conference on Lung Cancer Lancet Oncol. (IF 54.433) Pub Date : 2022-08-11 Flávia Oliveira Geraldes
Abstract not available
-
De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study Lancet Oncol. (IF 54.433) Pub Date : 2022-08-08 Sabine R de Wild, Linda de Munck, Janine M Simons, Janneke Verloop, Thijs van Dalen, Paula H M Elkhuizen, Ruud M A Houben, A Elise van Leeuwen, Sabine C Linn, Ruud M Pijnappel, Philip M P Poortmans, Luc J A Strobbe, Jelle Wesseling, Adri C Voogd, Liesbeth J Boersma
Background Primary chemotherapy in breast cancer poses a dilemma with regard to adjuvant locoregional radiotherapy, as guidelines for locoregional radiotherapy were originally based on pathology results of primary surgery. We aimed to evaluate the oncological safety of de-escalated locoregional radiotherapy in patients with cT1–2N1 breast cancer treated with primary chemotherapy, according to a predefined
-
Customising radiotherapy in stage II breast cancer after primary chemotherapy Lancet Oncol. (IF 54.433) Pub Date : 2022-08-08 Youlia Kirova, Pierre Loap
Abstract not available
-
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial Lancet Oncol. (IF 54.433) Pub Date : 2022-08-08 Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely, Amanda Hayman, David O'Brien, Rehan Ahmad, Jeffrey V Manchio, Nathaniel Fox, Kayla McCarty, Michaela Phillips, Evelyn Brosnan, Gina Vaccaro, Rui Li, Miklos Simon, Eric Bernstein, Mary McCormick, Kristina H Young
Background TGF-β is an immunosuppressive cytokine that is upregulated in colorectal cancer. TGF-β blockade improved response to chemoradiotherapy in preclinical models of colorectal adenocarcinoma. We aimed to test the hypothesis that adding the TGF-β type I receptor kinase inhibitor galunisertib to neoadjuvant chemoradiotherapy would improve pathological complete response rates in patients with locally
-
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study Lancet Oncol. (IF 54.433) Pub Date : 2022-08-05 Reinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, Youyou Hu, Dao Wang, Sergio Jobim de Azevedo, Caroline Robert, Paolo Antonio Ascierto, Vanna Chiarion-Sileni, Paolo Pronzato, Francesco Spagnolo, Karmele Mujika Eizmendi, Gabriella Liszkay, Luis de la Cruz Merino, Hussein Tawbi
Background Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases. We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases. Methods TRICOTEL was a multicentre, open-label, single-arm
-
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial Lancet Oncol. (IF 54.433) Pub Date : 2022-08-04 Neeta Somaiah, Anthony P Conley, Edwin Roger Parra, Heather Lin, Behrang Amini, Luisa Solis Soto, Ruth Salazar, Carmelia Barreto, Honglei Chen, Swati Gite, Cara Haymaker, Elise F Nassif, Chantale Bernatchez, Akash Mitra, John Andrew Livingston, Vinod Ravi, Dejka M Araujo, Robert Benjamin, Patrick Hwu
Background Few standard treatment options are available for patients with metastatic sarcomas. We did this trial to evaluate the efficacy, safety, and changes in the tumour microenvironment for durvalumab, an anti-PD-L1 drug, and tremelimumab, an anti-CTLA-4 drug, across multiple sarcoma subtypes. Methods In this single-centre phase 2 trial, done at The University of Texas MD Anderson Cancer Center
-
IAEA expresses concern over situation at Zaporizhzya Nuclear Power Plant Lancet Oncol. (IF 54.433) Pub Date : 2022-08-04 Manjulika Das
Abstract not available
-
Centralisation of oncology surgery services Lancet Oncol. (IF 54.433) Pub Date : 2022-08-02 Jan Sorensen
Abstract not available
-
Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study Lancet Oncol. (IF 54.433) Pub Date : 2022-08-02 Ajay Aggarwal, Lu Han, Stephanie van der Geest, Daniel Lewis, Yolande Lievens, Josep Borras, David Jayne, Richard Sullivan, Marco Varkevisser, Jan van der Meulen
Background Centralisation of specialist cancer services is occurring in many countries, often without evaluating the potential impact before implementation. We developed a health service planning model that can estimate the expected impacts of different centralisation scenarios on travel time, equity in access to services, patient outcomes, and hospital workload, using rectal cancer surgery as an example
-
Thank you and farewell: cancer control and Japan's former Prime Minister Shinzo Abe Lancet Oncol. (IF 54.433) Pub Date : 2022-07-28 Yusuke Tanaka
Abstract not available
-
Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed? Lancet Oncol. (IF 54.433) Pub Date : 2022-07-28 Arielle Elkrief, Helena Yu
Abstract not available
-
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial Lancet Oncol. (IF 54.433) Pub Date : 2022-07-28 Shun Lu, Lin Wu, Hong Jian, Ying Chen, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Meili Sun, Liang Han, Liyun Miao, Cuimin Ding, Jiuwei Cui, Baolan Li, Yueyin Pan, Xingya Li, Feng Ye, Anwen Liu, Chengli Zhang
Background VEGF inhibitors can enhance the efficacy of immunotherapy. However, despite high initial response rates, almost all patients eventually develop treatment resistance to EGFR tyrosine-kinase inhibitors. We aimed to evaluate the efficacy and safety of sintilimab with or without IBI305 plus pemetrexed and cisplatin, compared with pemetrexed and cisplatin alone, for the treatment of patients
-
Progress on tobacco control and e-cigarettes Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 The Lancet Oncology
Abstract not available
-
Coordinated efforts to harmonise gynaecological cancer care Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Márcia Costa, Cheryl Lai
Abstract not available
-
Problems with catch-up HPV vaccination after resumption of proactive recommendations Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Masayuki Sekine, Manako Yamaguchi, Risa Kudo, Sharon J B Hanley, Yutaka Ueda, Megumi Kurosawa, Sosuke Adachi, Etsuko Miyagi, Megumi Hara, Takayuki Enomoto
Abstract not available
-
The impact of the EU General Data Protection Regulation on childhood cancer research in Europe Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Gilles Vassal, Deyan Lazarov, Carmelo Rizzari, Tomasz Szczepański, Ruth Ladenstein, Pamela R Kearns
Abstract not available
-
Project Orbis: the UK experience after 1 year Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Mark P Lythgoe, Richard Sullivan
Abstract not available
-
Surrogate endpoints in breast cancer screening trials Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Ismail Jatoi
Abstract not available
-
Surrogate endpoints in breast cancer screening trials – Authors' reply Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Walter Heindel, Stefanie Weigel, Hans-Werner Hense
Abstract not available
-
PI3K inhibitors in haematological malignancies Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 David J Benjamin, Vinay Prasad
Abstract not available
-
PI3K inhibitors in haematological malignancies Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Jennifer R Brown, Alexey V Danilov, Ann S LaCasce, Matthew S Davids
Abstract not available
-
PI3K inhibitors in haematological malignancies Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Matthew J Matasar, Florian Hiemeyer, Barrett H Childs, Pier Luigi Zinzani
Abstract not available
-
MRI in the prognostic evaluation of patients with rectal cancer Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Qingkun Gao, Zhaoya Gao, Juan Wang, DanDan Huang, Jin Gu
Abstract not available
-
MRI in the prognostic evaluation of patients with rectal cancer – Authors' reply Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Gina Brown
Abstract not available
-
New legislation to promote paediatric studies for new cancer medicines Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Thomas J Hwang, Florence T Bourgeois
Abstract not available
-
Correction to Lancet Oncol 2022; 23: 950–60 Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25
Abstract not available
-
Correction to Lancet Oncol 2022; 23: 990 Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25
Abstract not available
-
Correction to Lancet Oncol 2022; 23: 1097–108 Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25
Abstract not available
-
ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Michele Milella, Rita T Lawlor, Claudio Luchini, Amber L Johns, Raffaella Casolino, Takayuki Yoshino, Andrew V Biankin, Aldo Scarpa
Abstract not available
-
Early evidence for cancer in Sudan: an advanced example of bone metastases from ancient Nubia (circa 2500–2050 BCE) Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Rebecca Whiting, Emma L W Phillips, Daniel O'Flynn, Daniel Antoine
Abstract not available
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Ignace Vergote, Antonio Gonzalez-Martin, Domenica Lorusso, Charlie Gourley, Mansoor Raza Mirza, Jean-Emmanuel Kurtz, Aikou Okamoto, Kathleen Moore, Frédéric Kridelka, Iain McNeish, Alexander Reuss, Bénédicte Votan, Andreas du Bois, Sven Mahner, Isabelle Ray-Coquard, Elise C Kohn, Jonathan S Berek, David S P Tan, Jianqing Zhu
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated
-
Terminology for cone dimensions after local conservative treatment for cervical intraepithelial neoplasia and early invasive cervical cancer: 2022 consensus recommendations from ESGO, EFC, IFCPC, and ESP Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Maria Kyrgiou, Antonios Athanasiou, Marc Arbyn, Sigurd F Lax, Maria Rosaria Raspollini, Pekka Nieminen, Xavier Carcopino, Jacob Bornstein, Murat Gultekin, Evangelos Paraskevaidis
Local cervical treatment for squamous intraepithelial lesion (SIL) or cervical intraepithelial neoplasia (CIN) removes or ablates a cone-shaped or dome-shaped part of the cervix that contains abnormal cells. This Series paper introduces the 2022 terminology for cone dimensions after local conservative treatment for SIL, CIN, or early invasive cervical cancer. The terminology was prepared by the Nomenclature
-
Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Holly B Lindsay, Maura Massimino, Shivaram Avula, Stavros Stivaros, Richard Grundy, Katie Metrock, Aashim Bhatia, Ana Fernández-Teijeiro, Luisa Chiapparini, Jeffrey Bennett, Karen Wright, Lindsey M Hoffman, Amy Smith, Kristian W Pajtler, Tina Young Poussaint, Katherine E Warren, Nicholas K Foreman, David M Mirsky
Response criteria for paediatric intracranial ependymoma vary historically and across different international cooperative groups. The Response Assessment in the Pediatric Neuro-Oncology (RAPNO) working group, consisting of an international panel of paediatric and adult neuro-oncologists, neuro-radiologists, radiation oncologists, and neurosurgeons, was established to address both the issues and the
-
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis? Lancet Oncol. (IF 54.433) Pub Date : 2022-07-25 Michael Moryoussef, Sébastien Mulé, Florian Gerbaud, Julien Haroche, Marie Matignon, Nizar Joher
Abstract not available
-
Correction to Lancet Oncol 2022; 23 (Abstracts from the The Lancet Summit: Cancer care in Asia and Latin America Special Issue): S11 Lancet Oncol. (IF 54.433) Pub Date : 2022-07-20
Abstract not available
-
Members of parliament debate assisted dying in response to a petition calling for a change in the law Lancet Oncol. (IF 54.433) Pub Date : 2022-07-14 Emma Wilkinson
Abstract not available
-
Peru faces shortage of cancer drugs Lancet Oncol. (IF 54.433) Pub Date : 2022-07-14 Manjulika Das
Abstract not available
-
Cancer survival rates in Scotland Lancet Oncol. (IF 54.433) Pub Date : 2022-07-14 Talha Khan Burki
Abstract not available
-
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study Lancet Oncol. (IF 54.433) Pub Date : 2022-07-12 Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essell, Rajneesh Nath, Scott R Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel Gupta, Ronald Dubowy, Aleco D'Andrea, Leo I Gordon
Background Patients with relapsed or refractory large B-cell lymphoma after first-line treatment who are not intended for haematopoietic stem-cell transplantation (HSCT) have poor outcomes and limited treatment options. We assessed the antitumour activity and safety of lisocabtagene maraleucel, an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell product, as second-line treatment in
-
Optical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial Lancet Oncol. (IF 54.433) Pub Date : 2022-07-11 Fieke Adan, Patty J Nelemans, Brigitte A B Essers, Tjinta Brinkhuizen, Sharon R P Dodemont, Janneke P H M Kessels, Patricia J F Quaedvlieg, Gert-Jan Dermont, Veronique J L Winnepenninckx, Myrurgia Abdul Hamid, Nicole W J Kelleners-Smeets, Klara Mosterd
Background Punch biopsy is the gold standard for diagnosis and subtyping of basal cell carcinoma. The aim of this study was to assess whether use of optical coherence tomography (OCT), a non-invasive imaging tool, might avoid the need for biopsy. Methods In a multicentre, randomised, non-inferiority trial, patients (aged ≥18 years) with an indication for biopsy of a suspected basal cell carcinoma outside
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial Lancet Oncol. (IF 54.433) Pub Date : 2022-07-11 John M Pagel, Jacob D Soumerai, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Adam Asch, Huda Salman, Vaishalee P Kenkre, Alexia Iasonos, Judith Llorin-Sangalang, Joanne Li, Andrew D Zelenetz
Background Phosphatidylinositol 3-kinase p110δ (PI3Kδ) inhibitors are efficacious in B-cell malignancies. Immune-related adverse events might be mitigated with intermittent dosing. We aimed to evaluate the safety and antitumour activity of zandelisib, a potent novel PI3Kδ inhibitor, with continuous or intermittent dosing as monotherapy or in combination with rituximab, in patients with relapsed or
-
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis Lancet Oncol. (IF 54.433) Pub Date : 2022-07-11 Antonios Athanasiou, Areti Angeliki Veroniki, Orestis Efthimiou, Ilkka Kalliala, Huseyin Naci, Sarah Bowden, Maria Paraskevaidi, Marc Arbyn, Deirdre Lyons, Pierre Martin-Hirsch, Phillip Bennett, Evangelos Paraskevaidis, Georgia Salanti, Maria Kyrgiou
Background The trade-off between comparative effectiveness and reproductive morbidity of different treatment methods for cervical intraepithelial neoplasia (CIN) remains unclear. We aimed to determine the risks of treatment failure and preterm birth associated with various treatment techniques. Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane
-
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial Lancet Oncol. (IF 54.433) Pub Date : 2022-07-11 Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, Nelly Firmin, Pascaline Boudou-Rouquette, François Bertucci, Corinne Balleyguier, Valérie Lebrun-Ly, Isabelle Ray-Coquard, Elsa Kalbacher, Aurélie Bardet, Emmanuelle Bompas, Olivier Collard, Nicolas Isambert, Cécile Guillemet, Maria Rios, Esma SAADA-BOUZID
Background Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin alone is used as the standard first-line treatment. Doxorubicin combined with trabectedin has shown promising results in phase 1 and 2 studies. We aimed to identify and compare the progression-free survival of patients with metastatic or unresectable uterine or soft tissue leiomyosarcoma treated with doxorubicin
-
Extreme weather, natural disasters, and cancer care Lancet Oncol. (IF 54.433) Pub Date : 2022-07-08 Talha Khan Burki
Abstract not available
-
ESMO World Congress on Gastrointestinal Cancer 2022 Lancet Oncol. (IF 54.433) Pub Date : 2022-07-07 Katherine Gourd
Abstract not available
-
Cancer research investment could boost UK economy Lancet Oncol. (IF 54.433) Pub Date : 2022-07-07 Elizabeth Gourd
Abstract not available
-
Zanubrutinib joins the CLL treatment buffet Lancet Oncol. (IF 54.433) Pub Date : 2022-07-07 Pablo Mozas, Julio Delgado
Abstract not available
-
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial Lancet Oncol. (IF 54.433) Pub Date : 2022-07-07 Constantine S Tam, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M Brander, Peter Hillmen
Background Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine–rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL. Methods We conducted an open-label, multicentre, phase 3 study at 153 academic
-
Pancreatic cancer: still a cold case? Lancet Oncol. (IF 54.433) Pub Date : 2022-07-07 Michele Reni, Giulia Orsi
Abstract not available
-
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial Lancet Oncol. (IF 54.433) Pub Date : 2022-07-07 Kim A Reiss, Rosemarie Mick, Ursina Teitelbaum, Mark O'Hara, Charles Schneider, Ryan Massa, Thomas Karasic, Rashmi Tondon, Chioma Onyiah, Mary Kate Gosselin, Alyssa Donze, Susan M Domchek, Robert H Vonderheide
Background Establishing alternatives to lifelong chemotherapy for patients with advanced pancreatic cancer has been proposed to address chemotherapy resistance and cumulative toxicity. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in this setting, and concurrent immune checkpoint blockade could offer synergistic tumour control. The aim of this study was to test the safety and antitumour
-
Managing immune checkpoint inhibition in transplant recipients Lancet Oncol. (IF 54.433) Pub Date : 2022-07-06 Céleste Lebbé, Lucie Biard, Julie Delyon, Julien Zuber
Abstract not available
-
Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study Lancet Oncol. (IF 54.433) Pub Date : 2022-07-06 Robert P Carroll, Michael Boyer, Val Gebski, Bronwyn Hockley, Julie K Johnston, Svjetlana Kireta, Hsiang Tan, Anne Taylor, Kate Wyburn, John R Zalcberg
Background Most kidney transplant recipients with cancer stop or reduce immunosuppressive therapy before starting treatment with an immune checkpoint inhibitor, and approximately 40% of such patients will develop allograft rejection. Isolated immunosuppression reduction might be associated with organ rejection. Whether immunosuppression manipulation, immune checkpoint inhibition, or both, induce organ
-
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study Lancet Oncol. (IF 54.433) Pub Date : 2022-07-05 Lihua E Budde, Laurie H Sehn, Matthew Matasar, Stephen J Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta Nastoupil, Chan Yoon Cheah, Michael C Wei, Shen Yin, Chi-Chung Li, Huang Huang, Antonia Kwan, Nancy L Bartlett
Background Mosunetuzumab is a CD20 × CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. In a phase 1 study, mosunetuzumab was well tolerated and active in patients with relapsed or refractory B-cell lymphoma. We, therefore, aimed to evaluate the safety and anti-tumour activity of fixed-duration mosunetuzumab in patients with relapsed or refractory
-
Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma Lancet Oncol. (IF 54.433) Pub Date : 2022-07-05 Christian Buske
Abstract not available
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial Lancet Oncol. (IF 54.433) Pub Date : 2022-07-04 Robin Kate Kelley, Lorenza Rimassa, Ann-Lii Cheng, Ahmed Kaseb, Shukui Qin, Andrew X Zhu, Stephen L Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek-Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Thomas Yau
Background Cabozantinib has shown clinical activity in combination with checkpoint inhibitors in solid tumours. The COSMIC-312 trial assessed cabozantinib plus atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. Methods COSMIC-312 is an open-label, randomised, phase 3 trial that enrolled patients aged 18 years or older with advanced hepatocellular carcinoma
-
Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy Lancet Oncol. (IF 54.433) Pub Date : 2022-07-04 Fanpu Ji, Mindie H Nguyen
Abstract not available
-
War in Ukraine creates challenges for the cancer care system in Poland Lancet Oncol. (IF 54.433) Pub Date : 2022-07-01 Joanna A Didkowska, Klaudia Barańska, Urszula Wojciechowska, Jerzy E Tyczyński
Abstract not available